Bibliograf™abis.qxd

Bibliografía
1. Banegas JR, Rodríguez-Artalejo F, de la Cruz Troca JJ, Gua- 13a. The ALLHAT Officers and Coordinators for the ALLHAT llar-Castillón P, del Rey Calero J. Blood pressure in Spain.
Collaborative Research Group. Major outcomes in high- Distribution, awareness, control and benefits of a reduction risk hypertensive patients randomized to angiotensin con- in average pressure. Hypertension 1998;32: 998-1002.
verting enzyme inhibitor or calcium channel blocker vs 2. Coca Payeras A. Evolución del control de la hipertensión diuretic: tha Antihypertensive and Lipid-Lowering Treat- arterial en España. Resultados del estudio Controlpres ment to Prevent Heart Attack Trial (ALLHAT). JAMA 2a. Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, 14. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Luque M, de la Cruz Troca J, et al. Hypertension magni- Andersen S, Arner P, et al. The effect of irbesartan on the tude and management in the elderly populations of Spain.
development of diabetic nephropathy in patients with ty- pe 2 diabetes. N Engl J Med 2001;345:870-8.
3. Ministerio de Sanidad y Consumo. Sociedad-Liga Españo- 15. Lewis ED, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Le- la para la Lucha contra la Hipertensión Arterial. Control wis JB, et al. Renoprotective effect of the angiotensin-re- de la hipertensión arterial en España, 1996. Madrid: Mi- ceptor antagonist irbesartan in patients with nephropathy nisterio de Sanidad y Consumo; 1996.
due to type 2 diabetes. N Engl J Med 2001;345:851-60. 4. Joint National Committee on Detection, Evaluation, and 16. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch treatment of High Blood Pressure. The Sixth Report of the WE, Parving HH, et al. Effects of losartan on renal and Joint National Committee on Prevention, Detection, Eva- cardiovascular outcomes in patients with type 2 diabetes luation, and Treatment of High Blood Pressure. Arch In- and nephropathy. N Engl J Med 2001;345:861-9. 17. Pitt B, Poole-Wilson PA, Segal R, Martinez F, Dickstein K, 5. Guideliness Subcommittee. 1999 World Health Organiza- Camm AF, et al. Effect of losartan compared with capto- tion-International Society of Hypertension Guidelines for the pril on mortality in patients with symptomatic heart failu- Management of Hypertension. J Hypertens 1999; 17:151-83.
re: randomised trial –the Losartan Heart Failure Survival 6. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Pos- Study- ELITE II. Lancet 2000;355;1582-7. ton L, Poulter NR, et al. Guidelines for management of hy- 18. Cohn J, Tognoni G, for the Val-HeFT Investigators. A ran- pertension: report of the third working party of the British domized trial of the angiotensin receptor blocker valsartan Hypertension Society. J Hum Hypertens 1999;13:569-92.
in chronic heart failure. N Engl J Med 2001:345:1667-75.
7. Staessen JA, Fagard R, Thijs L, Cells H, Arabizde CG, Bir- 19. PROGRESS Collaborative Group. Randomised trial of a kenhager WH, et al for the Systolic Hypertension in Euro- perindopril-based blood-pressure-lowering regimen pe (Syst-Eur) Trial Investigators. Randomised double-blind among 6105 individuals with previous stroke or transient comparison of placebo and active treatment for older pa- ischaemic attack. Lancet 2001;358:1033-41.
tients with isolated systolic hypertension. Lancet 1997; 20. Kannel WB. Fifty years of Framingham Study contribu- tions to understanding hypertension. J Hum Hypertens 8. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting enzyme 21. Carretero OA, Oparil S. Essential hypertension. Part I: de- inhibition compared with conventional therapy on car- finition and etiology. Circulation 2000;101:329-35.
diovascular morbidity and mortality in hypertension: the 22. Kaplan NM. Hypertension in the population at large.
Captopril Prevention Project (CAPPP) randomized trial.
En: Kaplan NM, editor. Clinical Hypertension. 7th ed.
Baltimore: Williams & Wilkins; 1998. p. 1-17.
9. Lindholm LH, Hansson L, Ekbom T, Dahlöf B, Lanke J, 23. Gabriel R, Labarthe DR, Forthofer R, Fernández-Cruz A, Linjer J, et al. Comparison of antihypertensive treatments for the Spanish Group for the Study of Cardiovascular Risk in preventing cardiovascular events in elderly diabetic pa- Factors in Childhood and Youth. National standards for tients: results from the Swedish Trial in Old Patients with blood pressure for children and adolescents in Spain. In- Hypertension-2. Stop Hypertension-2 Study Group. J Hy- ternational comparisons. Int J Epidemiol 1992;2:1-10.
24. Grupo Cooperativo Español para el Estudio de los Facto- 10. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia res de Riesgo Cardiovascular en la Infancia y Adolescen- G, Rosenthal T, et al. Morbidity and mortality in patients cia. Factores de riesgo cardiovascular en la infancia y randomised to double-blind treatment with a long-acting adolescencia en España. Estudio RICARDIN II: principales calcium-channel blocker or diuretic in the international valores de referencia. An Esp Pediatr 1995;43:11-7.
nifedipine GITS study: intervention as a goal in hyperten- 25. National High Blood Pressure Education Program Wor- sion treatment (INSIGHT). Lancet 2000;356:366-72. king Group on High Blood Pressure in Pregnancy. Report 11. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lind- of the National High Blood Pressure Education Program holm LH, Syversten JO, et al. Randomised trial of effects Working Group on High Blood Pressure in Pregnancy.
of calcium and β-blockers on cardiovascular morbidity Am J Obstet Gynecol 2000;183:S1-S22.
and mortality in hypertension: the Nordic Diltiazem 26. Franklin SS, Gustin W, Wong WG, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-re- 12. He J, Whelton PK. Selection of initial antihypertensive lated changes in blood pressure. The Framingham Heart drug therapy. Lancet 2000;356:1942-3.
13. Lip GYH, Beevers DG. Calcium channel blockers in hyper- 27. Pardell H, Armario P, Hernández R, Tresserras R. Hyper- tension: the debate reawakens. J Hum Hypertens 2001; tension. Epidemiology and cost of illness. Dis Manage Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 28. Gabriel R, Alonso M, Bermejo F, Muñiz J, López I, Suárez 48. Lurbe E, Álvarez V, Liao Y, Tacons J, Cooper R, Cremades B, C, et al. Proyecto EPICARDIAN. Estudio epidemiológico et al. The impact of obesity and body fat distribution on sobre enfermedades y factores de riesgo cardiovasculares ambulatory blood pressure in children and adolescents.
en ancianos españoles: diseño, métodos y resultados pre- liminares. Rev Esp Geriatr Gerontol 1996;31:327-34.
49. Paffenbarger RS, Lee IM. Intensity of physical activity rela- 29. Armario Garcia P, Hernández del Rey R, Gasulla Roso ted to incidence of hypertension and all-cause mortality: an JM, Alonso Fresneda A, Tresserras R, Pardell Alenta P. Pre- epidemiologic view. Blood Press Monit 1997;2:115-23.
valencia de hipertensión arterial en L’Hospitalet de Llo- 50. Palatini P, Graniero GR, Mormino P, Nicolosi L, Mos L, bregat. Evolución de la tasa de control entre 1981 y 1987.
Visentin P, et al, for the Harvest Study Group. Relation between physical training and ambulatory blood pressure 30. Banegas Banegas JR, Rodríguez-Artalejo F, de La Cruz in stage I hypertensive subjects . Results of the HARVEST Troca JJ, de Andrés Manzano B, del Rey Calero J. Mortali- trial. Hypertension and Ambulatory Recording Venetia dad relacionada con la hipertensión y la presión arterial en España. Med Clin (Barc) 1999;112:489-94.
51. Abellán J, Armario P, editores. Hipertensión y reactividad 31. Black HR, Kuller LH, O’Rourke MF, Weber MA, Alder- cardiovascular (estrés y ejercicio). Grupos de Trabajo en Hi- man MH, Benetos A, et al. The first report of the Systolic pertensión. Madrid: Sociedad Española de Hipertensión/ Liga and Pulse Pressure (SYPP) Working Group. J Hypertens Española para la Lucha contra la Hipertensión Arterial; 1996.
52. Pickering TG. The effects of environmental and lifestyle fac- 32. Armario P, Hernández del Rey R, Ceresuela-Eito LM, Mar- tors on blood pressure and the intermediary role of sympat- tín-Baranera M. Presión del pulso como factor pronóstico hetic nervous system. J Hum Hypertens 1997;11(Suppl 1): en los pacientes hipertensos. Hipertensión 2000;17:325-31.
33. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, 53. Pickering TG, Devereux RB, James GD, Gerin W, Lands- Kannel WB, et al. Does the relation of blood pressure to bergis P, Schnall J, et al. Environmental influences on blo- coronary heart disease risk change with aging? The Fra- od pressure and the role of job strain. J Hypertens mingham Heart Study. Circulation 2001;103:1245-9.
34. Goldstein LB, Adams R, Becker K, Furgberg CD, Gorelick 54. James GD, Cates EM, Pickering TG, Laragh JH. Parity and PB, Hademenos G, et al. Primary prevention of ischemic perceived job stress elevate blood pressure in young nor- stroke: a statement for healthcare professionals from the motensive working women. Am J Hypertens 1989;2:637-9.
Stroke Council of the American Heart Association. Circu- 55. Safian RD. Textor SC. Renal-artery stenosis. N Engl J Med 35. Tresseras R, Serra-Majem L, Canela J, Armario P, Pardell 56. Stowasser M. Primary aldosteronism: a revival of a syn- H, Rue M, et al. Ecological association between hyperten- sion and stroke in Catalonia (Spain): development and use 57. Kaplan NM. Cautions over the current epidemic of pri- of an ecological regression model. J Hum Hypertens mary aldosteronism. Lancet 2001;357:953-4.
58. Pacack K, Linehan WM, Eisenhofer G, Walther MM, 36. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton Goldstein DS. Recent advances in genetics, diagnosis, lo- J, et al. Blood pressure, stroke, and coronary heart disea- calization, and treatment of pheochromocytoma. Ann In- se. Part 1, prolonged differences in blood pressure: pros- pective observational studies corrected for the regression 59. Witteles RA, Kaplan EL, Roizen MF. Sensitivity of diagnos- dilution bias. Lancet 1990;335:765-74.
tic and localization tests for pheochromocytoma in clini- 37. Vasan RS, Levy D. The role of hypertension in the patho- cal practice. Arch Intern Med 2000;160:2521-4.
genesis of heart failure. A clinical mechanistic overview.
60. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, et al. Diagnostic efficacy of unconjugated 38. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, plasma metanephrines for the detection of pheochro- Ford CE, et al. Blood pressure and end-stage renal disease mocytoma. Arch Intern Med 2000;160:2957-63.
61. Daniels SR. Repair of coarctation of the aorta and hyper- 39. Williams SM, Addy JH, Phillips III JA, Dai M, Kpodonou J, tension: does age matter? Lancet 2001;358:89.
Afful J, et al. Combinations of variations in multiple genes are 62. Pickering TG. The influence of daily activity on ambula- associated with hypertension. Hypertension 2000;36:2-6.
tory blood pressure. Am Heart J 1988;116:1141-5.
40. Baker DJP. The fetal origins of hypertension. J Hypertens 63. Bailey RH, Bauer JH. A review of common errors in the indirect measurement of blood pressure. Sphygmomano- 41. Singhal A, Cole TJ, Lucas A. Early nutrition in preterm in- meter. Arch Intern Med 1993;153:27-41.
fants and later blood pressure: two cohorts after randomi- 64. Pickering TG, Schnall PL, Schwartz JE, Pieper CF. Can be- havioral factors produce a sustained elevation of blood 42. Brenner BM, Chertow GM. Congenital oligonephropathy pressure? Some observations and a hypothesis. J Hyper- and the etiology of adult hypertension and progressive re- nal injury. Am J Kidney Dis 1994;23:171-5.
65. Mancia,G, Parati G, Pomidossi G, Grassi G, Casadei R, 43. Law MR. Epidemiologic evidence on salt and blood pres- Zanchetti A. Alerting reaction and rise in blood pressure sure. Am J Hypertens 1997;10 (5 Pt 2):42S-45S.
during measurement by physician and nurse. Hyperten- 44. Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernán- dez-Solá J, Urbano-Márquez A. Effect of alcohol abstinen- 66. Bottini P, Carr A, Prisant L, Rhoades R. Variability and si- ce on blood pressure: assessment by 24-hour ambulatory milarity of manual office and automated blood pressures. blood pressure monitoring. Hypertension 1999;33:653-7.
45. Armario García P, Hernández del Rey R, Gasulla Roso 67. Pickering TG, James GD, Boddie C, Harshfield GA, Blank JM, Pardell H. Obesidad e hipertensión arterial. Estudio S, Laragh JH. How common is white coat hypertension? JA- transversal de prevalencia en la población de L’Hospitalet de Llobregat. Rev Clin Esp 1990;187:223-8.
68. Recommendations for routine blood pressure measure- 46. Aranceta J, Pérez C, Serra L, Ribas L, Quiles J, Vioque J, et ment by indirect cuff sphygmomanometry. American So- al, y Grupo Colaborativo Español para el Estudio de la ciety of Hypertension. Am J Hypertens 1992;5:207-9.
Obesidad. Prevalencia de la obesidad en España: estudio 69. Kaplan NM. Measurement of blood pressure. En: Kaplan SEEDO´97. Med Clin (Barc) 1998;111:441-5.
NM, editor. Clinical hypertension. Baltimore: Williams 47. Wolf HK, Tuomilehto J, Kuulasmaa K, Domarkiene S, Ce- paitis Z, Molarius A, et al. Blood pressure levels in the 41 69a. Lane D, Beevers M, Barnes N, Bourne J, John A, Malins S, populations of the WHO MONICA Project. J Hum Hyper- Beevers DG. Inter-arm differences in blood pressure: when are they clinically significant? J Hypertens 2002;20:1089-95.
Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 70. Beevers G, Lip GYH, O’Brien E. Blood pressure measure- 91. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al.
ments. Part I. Sphygmomanometry: factors common to all Home blood pressure measurement has a stronger predic- tive power for mortality that does screening blood pressu- 71. Whelton A. Application of ambulatory blood pressure re: a population-based observation in Ohasama, Japan. J monitoring to clinical therapeutic decisions in hyperten- sion. J Hypertens Suppl 1991;9(Suppl 1):S21-S25.
92. Asmar R. Proceedings from the First International Consen- 72. Pickering TG. A review of national guidelines on the cli- sus Conference on Self-blood Pressure Measurement. Blood nical use of ambulatory blood pressure monitoring. Blood 93. Asmar R, Zanchetti A. Guidelines for the use of self blood 73. Staessen JA, Thijs L. Development of diagnostic thresholds pressure monitoring: a summary report of the first interna- for automated self-measurement of blood pressure in adults, tional consensus conference. J Hypertens 2000;18:493-508.
First International Consensus Conference on Blood Pressure 93a. Yarows SA, Staessen JA. How to use home blood pressu- Self-Measurement. Blood Press Monit 2000; 5:101-9.
re monitors in clinical practice. Am J Hypertens 2002; 74. Ohkubo T, Imai Y, Tsuji I, Nagai K, Ito S, Satoh H, et al.
Reference values for 24-hour ambulatory blood pressure 94. Pickering, TG, for an American Society of Hypertension monitoring based on a prognostic criterio: the Ohasama Ad Hoc Panel. Recommendations for use of home (self) and ambulatory blood pressure monitoring. Am J Hyper- 75. Schettini C, Bianchi M, Nieto F, Sandoya E, Senra H, the Hypertension Working Group. Ambulatory blood pressu- 94a. Kikuya M, Chonan K, Imai Y, Goto E, Ishii M. Accuracy re: normality and comparison with other measurements.
and reliability of wrist-cuff devices for self measurement of blood pressure. J Hypertens 2002;20:629-38.
76. Verdechia P, Clement D, Fagard R. Target organ damage, 94b. Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Ba- morbidity and mortality. Blood Press Monit 1999;4:303-17.
rron A, Mant D. Comparison of agreement between diffe- 77. Pickering TG, Coats A, Mallion JM, Mancia G, Verdec- rent measures of blood pressure in primary care and day- chia P. Task force V:white-coat hypertension. Blood Press time ambulatory blood pressure. BMJ 2002;325:254-9.
95. De la Sierra A, Coca A. Evaluación clínica y diagnóstico 78. Verdecchia P, Porcellati C, Schillaci C, Borglioni C, Ciucci A, diferencial del paciente hipertenso. En Coca A, de la Sie- Batistelli M. Ambulatory blood pressure. An independent rra A, editores. Decisiones clínicas y terapéuticas en el predictor of prognosis in essential hypertension. Hyper- paciente hipertenso. 2.a ed. Barcelona: Editorial Médica 79. Perloff D, Sokolow M, Cowan R, Juster R. Prognostic va- 96. Messerli FH, Frohlich ED. High blood pressure, a side effect lue of ambulatory blood pressure measurements: further of drugs, poison and food. Arch Intern Med 1979;139:682-7.
analyses. J Hypertens 1989, 7 (Suppl 3):S3-S10.
97. Bulpitt CJ, Dollery CT, Crane S. Change in symptoms in 80. Khattar RS, Swales JD, Banfield A, Dore C, Senior R, Lahi- hypertensive patients after referral to hospital clinic. Br ri A. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pres- 98. Kruszewski P, Bieniaszewski L, Neubauer J, Krupa-Wojcie- sure monitoring in essential hypertension. Circulation 1999; chowska B. Headache in patients with mild to moderate 100: 1071-6. (Correction in Circulation 1999;100:1760).
hypertension is generally not associated with simultaneous 81. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, blood pressure elevation. J Hypertens 2000;18: 437-44.
et al. Prediction of mortality by ambulatory blood pressure 98a. Sierra C, de la Sierra A, Mercader J, Gómez-Angelats E, monitoring versus screening blood pressure measurements: Urbano-Márquez A, Coca A. Silent cerebral white matter a pilot study in Ohasama. J Hypertens 1997;15: 357-64.
lesions in middle-aged essential hypertensive patients. J 82. Staessen J, Thijs L, Fagard R, O'Brien E, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using con- 99. Ross EJ, Linch DC. Cushing's syndrome-killing disease: ventional vs ambulatory blood pressure in older patients discriminatory value of signs and symptoms aiding early with systolic hypertension. JAMA 1999;282:539-46.
83. Redón J, Campo C, Narciso ML, Rodicio JL, Pascual JM, 100. Klaff V, Shapiro B, Lloyd R, Sisson JC, Holland K, Nakajo M, Ruilope LM. Prognostic value of ambulatory blood pres- et al. Spectrum of pheochromocytoma in hypertensive pa- sure monitoring in refractory hypertension: a prospective tients with neurofibromatosis. Arch Intern Med 1982; 84. Jula A, Puukka P, Karanko H. Multiple clinic and home 101. Newman AB, Sutton-Tyrell K, Vogt MT, Kuller LH. Morbi- blood pressure measurements versus ambulatory blood dity and mortality in hypertensive adults with a low an- pressure monitoring. Hypertension 1999;34:261-6.
kle/arm blood pressure index. JAMA 1993;270:487-9.
85. Ohkubo T, Imai Y, Tsuji T, Nagai K, Watanabe N, Ninami N, 102. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, et al. Relation between nocturnal decline in blood pressu- Crager MA, Olin JW, et al. Peripheral arterial disease de- re and mortality: the Ohasama Study. Am J Hypertens 1997; tection, awareness, and treatment in primary care. JAMA 86. Zweiker R, Eber B, Schumacer M. Nondipping related to 103. Coca A, Ayuso C, Fontenla JR, Paré C, Ramírez J, de la cardiovascular events in essential hypertensive patients.
Sierra A. Atlas de evaluación clínica del paciente hiper- tenso. Ediciones Doyma, Barcelona 1998;1-177.
87. Mochizuki Y, Okutani M, Donfeng Y, Iwasaki H, Takusa- 104. Cockroft DW, Gault MH. Prediction of creatinine clearan- gawa M, Kohno I, et al. Limited reproducibility of circa- ce from serum creatinine. Nephron 1976;16:31-41. dian variation in blood pressure dippers and nondippers.
105. De la Sierra A, Ruilope LM. Treatment of hypertension in diabetes mellitus. Current Hypertension Reports 2000;2: 88. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien E, Fagard R, et al. Antihypertensive treatment based on con- 106. National Cholesterol Education Program. Third report of ventional or ambulatory blood pressure measurement. A the National Cholesterol Education Program (NCEP) Ex- randomized controlled trial. JAMA 1997;278:1065-72.
pert Panel on detection, evaluation, and treatment of high 89. O’Brien E, Waeber B, Parati G, Staessen J, Myers MG on blood cholesterol in adults (adult treatment panel III). Exe- behalf of the European Hypertension Society. Blood Pres- cutive summary. NIH Publication no. 01-3670, 2001;1-28.
sure measuring devices: recommendations of the Euro- 107. Fang J, Alderman MH. Serum uric acid and cardiovascular pean Society of Hypertension, BMJ 2001;322:531-5.
mortality: the NHANES I epidemiologic follow-up study, 90. Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, et al. White-coat versus sustained borderline hypertension 108. Sibai BM. Treatment of hypertension in pregnant women.
in Tecumseh, Michigan. Hypertension 1990;16:617-23.
Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 109. Viberti GC, Jarret RJ, Mahmud U, et al. Microalbuminuria 124. Lindholm L, Ejlertsson G, Schersten B. High risk of cere- as a predictor of clinical nephropathy in insulin-depen- bro-cardiovascular morbidity in well treated male hyper- dent diabetes mellitus. Lancet 1982;1:1430-2.
tensives: a retrospective study of 40-59-year-old hyperten- 109a. Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, sives in a Swedish primary care district . Acta Med Scand Hoogwerf B, et al, for the HOPE Study Investigators. Albu- minuria and risk of cardiovascular events, death, and he- 125. Isles CG, Walker LM, Beevers DG. Mortality in patients of the art failure in diabetic and nondiabetic individuals. JAMA Glasgow blood pressure clinic. J Hypertens 1986;4: 141-56.
126. Samuelsson O, Wilhelmsen L, Andersson OK, Pennert K, 109b. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeld- Berglund G. Cardiovascular morbidity in relation to chan- sen SE, Nieminen MS, et al. Microalbuminuria in hyper- ge in blood pressure and serum cholesterol levels in trea- tensive patients with electrocardiographic left ventricular ted hypertension: Results of the Primary Prevention Trial hypertrophy: the LIFE Study. J Hypertens 2002;20:405-12.
in Göteborg, Sweden. JAMA 1987;258:1768-76.
110. Agewall S, Wikstrand J, Ljungman S, Herlitz H, Fagerberg B.
127. Madhavan S, Alderman MH. The potential effect of blood Does microalbuminuria predict cardiovascular events in pressure reduction on cardiovascular disease: a cautio- nondiabetic men with treated hypertension? Risk Factor I nary note. Arch Intern Med 1981;141:1583-6.
110a. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de 128. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excre- Wester PO. Morbidity and mortality in the Swedish Trial tion predicts cardiovascular and noncardiovascular morta- in Old Patients with Hypertension (STOP-Hypertension).
lity in general population. Circulation 2002;106:1777-82.
111. Liese AD, Hense HW, Döring A, Stieber J, Keil U. Micro- 129. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, albuminuria, central adiposity and hypertension in the Schersten B, et al. Randomised trial of old and new an- non-diabetic urban population of the MONICA Augsburg tihypertensive drugs in elderly patients: cardiovascular survey 1994/95. J Human Hypertens 2001;15:799-804.
mortality and morbidity the Swedish Trial in Old Patients 111a. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, with Hypertension-2 study. Lancet 1999;354:1751-6.
Engelgau M, et al. Microalbuminuria in the US popula- 130. SHEP Cooperative Research Group. Prevention of stroke tion: Third National Health and Nutrition Examination by antihypertensive drug treatment in older persons with Survey. Am J Kidney Dis 2002;39:445-59.
isolated systolic hypertension: Final results of the systolic 112. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, hypertension in the Elderly Program (SHEP). JAMA 1991; Chaudhary BS, et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective va- 131. Liu L, Wang JG, Gong L, Liu G, Staessen J, for the Systolic lidation of improved criteria. J Am Coll Cardiol 1985; Hypertension in China (Syst-China) Collaborative Group.
Comparison of active treatment and placebo in older chi- 113. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: nese patients with isolated systolic hypertension. J Hyper- Relation of left ventricular mass and geometry to morbi- dity and mortality in uncomplicated essential hyperten- 132. Motro M, Shemesh J. Calcium channel blocker nifedipine sion. Ann Intern Med 1991;114:345-52.
slows down progression of coronary calcifications in hyper- 114. Guia pràctica. Hipertensió Arterial per a l’Atenció Primà- tensive patients compared with diuretics. Hypertension ria. Grup de treball en Hipertensió Arterial. Societat Cata- lana de Medicina Familiar i Comunitaria. 2.a ed. Barcelo- 133. The Danish Study Group on Verapamil in Myocardial In- farction. Effect of verapamil on mortality and major events 115. Kannel WB, Wilson WF. An update on coronary risk fac- after acute myocardial infarction (The Danish Verapamil tors. Med Clin North Am 1995;79:951-71.
Infarction Trial DAVIT II). Am J Cardiol 1990;66:779-85.
116. Sytkowski PA, D’Agostino RB, Belanger AJ, Kannel WB. Se- 134. The Multicenter Diltiazem Postinfarction Trial Research cular trends in long-term sustained hypertension, long-term Group. The effect of diltiazem on mortality and reinfarction treatment and cardiovascular mortality. The Framingham after myocardial infarction. N Eng J Med 1988;319: 385-92.
Heart Study 1950 to 1990. Circulation 1996;93:697-703.
135. The CONSENSUS Trial Study Group. Effects of enalapril 117. Multiple Risk Factor Intervention Trial. Mortality after 10 on mortality in severe congestive heart failure. Results of years for hypertensive participants in the Multiple Risk the Cooperative North Scandinavian Enalapril Survival Factor Intervention Trial. Circulation 1990;82:1616-28.
Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
118. Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tomás L, 136. The SOLVD Investigators. Effect of enalapril on survival in et al. Guías de práctica clínica de la Sociedad Española patients with reduced left ventricular ejection fractions de Cardiología en hipertensión arterial. Rev Esp Cardiol and congestive heart failure. N Engl J Med 1991;325: 118a. Prospective Studies Collaboration. Age-specific relevan- 137. MERIT-HF study Group. Effect of metoprolol CR/XL in chronic ce of usual blood pressure to vascular mortality: a meta- heart failure: Metoprolol CR/XL randomised intervention analysis of individual data for one million adults in 61 trial in congestive heart failure (MERIT-HF). Lancet prospective studies. Lancet 2002;360:1903-13.
119. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, 138. CIBIS-II Investigators and Committees. The cardiac insuffi- Eberlein KA, et al. Blood pressure, stroke, and coronary ciency bisoprolol study II (CIBIS II): a randomised trial.
heart disease. Part 2, short-term reductions in blood pres- sure: overview of randomised drug trials in their epide- 138a. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, miological context. Lancet 1990;335:827-38.
de Faire U, et al, for the LIFE study group. Cardiovascular 120. MacMahon S, Rodgers A. The effects of antihypertensive morbidity and mortality in the Losartan Intervention For treatment on vascular disease: reappraisal of the evidence Endpoint reduction in hypertension study (LIFE): a rando- in 1994. J Vasc Med Biol 1993;4:265-71.
mised trial against atenolol. Lancet 2002;359:995-1003.
121. Sackett DL, Haynes RB, Gibson ES. Randomized clinical 139. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Co- trial of strategies for improving medication compliance in llaborative Study Group. The effect of angiotensin-conver- primary hypertension. Lancet 1975;1:1205-7.
ting enzyme therapy on diabetic nephropathy. N Engl J 122. Puigventós F, Llodrá V, Vilanova M, Delgado O, Lázaro M, Forteza-Rey J, et al. Cumplimiento terapéutico en el trata- 140. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, miento de la hipertensión: 10 años de publicaciones en Remuzzi G. Renal function and requirement for dialysis España. Med Clin (Barc) 1997;109:702-6. in chronic nephropathy patients on long-term ramipril: 123. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihyper- REIN follow-up trial. Lancet 1998;352:1252-6.
tensive therapy on serum lipids. Ann Intern Med 1995; 141. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renoprotective properties of ACE-inhibition Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 in non-diabetic nephropathies with non-nephrotic protei- 158a. Mata P, de Oya M, Pérez-Jiménez F, Ros Rahola E. Dieta y enfermedades cardiovasculares. Recomendaciones de la 142. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic Sociedad Española de Arterioesclerosis. Clin Invest Arte- and diastolic, and cardiovascular risks: US population da- ta. Arch Intern Med 1993;153:598-615.
159. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use 143. Cruikshank JM, Thorp JM, Zacharias FJ. Benefits and poten- raises blood pressure in treated hypertensive subjects. A tial harm of lowering blood pressure. Lancet 1987;1:581-4.
randomized controlled trial. Lancet 1987;1:647-51.
144. Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witterman JCM, 160. Gordon T, Kannel WB. Drinking habits and cardiovascular Breteler MMB. J-shaped relation between blood pressure disease: the Framingham Study. Am Heart J 1983;105: and stroke in treated hypertensives. Hypertension 1999; 161. Marmot MG, Rose G, Shipley MJ, Thomas BJ. Alcohol 145. Somes GW, Pahor M, Shorr IR, Cushman WC, Applegate and mortality: a U-shaped curve. Lancet 1981;1:580-3.
WB. The role of diastolic blood pressure when treating isola- 162. Klatsky AL, Armstrong MA, Friedman GD. Alcohol and ted systolic hypertension. Arch Intern Med 1999;159:2004-9.
mortality. Ann Intern Med 1992;117:646-54.
146. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elm- 163. Gill JS, Zezulka AV, Shipley MJ, Gill SK, Beevers DG.
feldt D, Julius S, et al. Effects of intensive blood-pressure Stroke and alcohol consumption. N Engl J Med 1986; lowering and low-dose aspirin in patients with hyperten- sion: principal results of the Hypertension Optimal Treat- 164. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Henne- ment (HOT) randomised trial. Lancet 1998;351:1755-62.
kens CH. A prospective study of moderate alcohol con- 146a. Kjeldsen SE, Erdine s, Farsang C, Sleight P, Mancia G.
sumption and the risk of coronary disease and stroke in European Society of Hypertension Scientific Newsletter.
women. N Engl J Med 1988;319:267-73.
1999 WHO/ISH Hypertension guidelines-highlights & 165. Langer RD, Criqui MH, Reed DM. Lipoproteins and blood ESH update. J Hypertens 2002;20:153-5.
pressure as biological pathways for effect of moderate al- 147. McAlister FA, Levine M, Zarnke KB, Campbell N, Le- cohol consumption on coronary heart disease. Circula- wanczuch R, Leenen F, et al. The 2000 Canadian recom- mendations for the management of hypertension: part 165a. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, one-therapy. Can J Cardiol 2001;17:543-59.
Whelton PK. Effects of alcohol reduction on blood pressu- 148. Coca A. Actual blood pressure control: are we doing re: a meta-analysis of randomised controlled trials. Hyper- things right? J Hypertens 1998;16 (Suppl 1):s45-s51.
149. UK Prospective Diabetes Study Group. Tight blood pres- 165b. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA, sure control and risk of macrovascular and microvascular Stampfer MJ, Willet WC. Roles of drinking pattern and ty- complications in type 2 diabetes. BMJ 1998;317:703-13.
pe of alcohol consumed in coronary heart disease in men.
150. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascu- 166. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, lar complications in type 2 diabetes. BMJ 1998;317: 713-20.
Whelton PK. Dietary sodium intake and subsequent risk 151. Ruilope LM, Coca A. The role of combination therapy in of cardiovascular disease in overweight adults. JAMA the treatment of hypertension. Blood Pressure 1998;7 167. Tuomiletho J, Jousilahti P, Rastenyte D, Moltchanov V, 151a. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen Tanskanen A, Pietinen P. Urinary sodium excretion and TA, et al. Primary prevention of hypertension. Clinical and cardiovascular mortality in Finland: a prospective study.
public health advisory from the National High Blood Pressure Education Program. JAMA 2002;288:1882-8.
168. Yamori Y, Nara Y, Mizushima S, Sawamura M, Horie R.
151b. Flegal KM, Carroll MD, Ogden CL, Jonson CL. Prevalence Nutritional factors for stroke and major cardiovascular di- and trends in obesity among US adults, 1999-2000. JAMA seases: international epidemiological comparison of die- tary prevention. Health Report 1994;6:22-7.
152. Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J. Ha- 169. Alderman MH, Cohen H, Madhavan S. Dietary sodium zards of obesity: the Framingham experience. Acta Med intake and mortality: the National Health and Nutrition Examination survey (NHANES I) Lancet 1998;351:781-5.
153. Dyer AR, Elliott P, Shipley M, Stamler R, Stamler J. Body 170. Luque Otero M, Martell Claros M, Ruiz Fernández MD, mass index and associations of sodium and potassium Fernández-Cruz A, Fernández Pinilla C. Medidas no far- with blood pressure in INTERSALT. Hypertension 1994; macológicas en el tratamiento de la hipertensión arterial esencial. Rev Clin Esp 1986;179 (suppl 1):46-50.
154. Seidell JC, Visscher TL, Hougeveen RT. Overweight and 171. Law MR, Frost CD, Wald NJ. By how much does dietary obesity in the mortality rate data: current evidence and salt reduction lower blood pressure? III-Analysis of data research issues. Med Sci Sports Exerc 1999;31(Suppl 11): from trials of salt reduction. BMJ 1991;302:819-24.
172. Langford HG, Blaufox D, Oberman A. Dietary therapy 155. Modan M, Halkin H, Amog S, Lusky A, Eskol A, Shefi M, et slows the return of hypertension after stopping prolonged al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-17.
173. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, 155a. Janssen I, Katmarzyk PT, Ross R. Body mass index, waist Sacks FM, et al. A clinical trial of the effects of dietary circumference, and health risk. Evidence in support of patterns on blood pressure. DASH collaborative research current National Institutes of Health Guidelines. Arch Intern group. N Engl J Med 1997;336:1117-24.
174. Vollmer WM, Sacks FM, Ard A, Appel LJ, GA Bray, Si- 156. Field AE, Coakley EH, Must A, Spadano JL, Laird N, mons-Morton DG, et al. Effects of diet and sodium intake Dietz WH, et al. Impact of overweight on risk of develo- on blood pressure: subgroup analysis of the DASH-so- ping common chronic diseases during a 10- years period.
dium trial. Ann Intern Med 2001;135:1019-28.
175. Logan AG. Sodium sensitivity, not level of salt intake, pre- 157. Reisin E, Abel R, Modam M, Silverberg DS, Eliahou HE, dicts salt effects. Current Hypertens Reports 2000:2:115-9.
Modam B. Effect of weight loss without salt restriction on 175a. Whelton SP, Chin A, Xin X, He J. Effect of anaerobic exercise the reduction of blood pressure in overweight hypertensi- on blood pressure: a meta-analysis of randomized, controlled ve patients. N Engl J Med 1978;298:1-6.
trials. Ann Intern Med 2002;136:493-503.
158. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Lang- 176. Fagard RH. The role of exercise in blood pressure control: ford HG, Davis BR, Wylie-Rosett J. The trial of Antihyper- Supportive evidence. J Hypertens 1995;13:1223-7.
tensive Intervention and Management (TAIM) Study. Arch 176a. Khalili P, Nilsson PM, Nilsson JA, Berglund G. Smoking as a modifier of the systolic blood pressure-induced risk Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 of cardiovascular events and mortality: a population-ba- antihypertensive therapies: a meta-analysis of randomised sed prospective study of middle-aged men. J Hypertens controlled trials. Lancet 2000;356:1949-54.
195. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al.
177. Hammond EC, Horn D, Smoking and death rates-report Shanghai trial of nifedipine in the elderly (STONE). J Hy- on forty-four months of follow-up of 187.783 men. I. To- tal mortality. JAMA 1958;166:1159-72.
196. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hy- 178. Kaplan NM. Treatment of hypertension: drug therapy. pertension in China (Syst-China) Collaborative Group.
En: Kaplan NM, editor. Clinical Hypertension 7th Ed. Bal- Chinese trial on isolated systolic hypertension in the el- timore: Williams & Wilkins; 1998. p. 181-263.
derly. Arch Intern Med 2000;160:211-20.
179. Blood Pressure Lowering Treatment Trialists´ Collabora- 197. Packer M, O´Conner CM, Ghali JK, Pressler ML, Carson PE, tion. Effect of ACE inhibitors, calcium antagonists, and other Belkin RN, et al, for the Prospective Randomized Amlodi- blood-pressure-lowering drugs: results of prospectively pine Survival Evaluation Study Group. Effect of amlodipi- designed overviews of randomised trial. Lancet 2000; ne on morbidity and mortality in severe chronic heart fai- lure. N Engl J Med 1996;335:1107-14.
180. Staessen JA, Wang JG, Thijs L. Cardiovascular protection 198. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Man- and blood pressure reduction: a meta-analysis. Lancet cini GBJ, Miller ME, et al, for the PREVENT Investigators.
Effect of amlodipine on the progression of atherosclerosis 181. Alcazár JM. Tratamiento de la hipertensión arterial. En: and the occurrence of clinical events. Circulation 2000; Hernando L, Aljama P, Arias M, Caramelo C, Egido J, La- mas S, editores. Nefrologia clínica. Madrid: Editorial Mé- 199. Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, dica Panamericana; 1997. p. 193-201.
Zanchett A. Clinical results of the Verapamil in Hyperten- 182. Alcázar JM. Hipertensión arterial. En: Lorenzo V, Torres A, sion and Atherosclerosis Study. J Hypertens 1997;15: Hernández D, Ayus JC, editores. Nefrología clínica, diálisis y trasplante renal. Madrid: Harcourt Brace; 1997. p. 215-58.
199a. Zanchetti A, Bond G, Henning M, Neiss A, Mancia G, 183. Flack JM, Cushman W. Evidence for the efficacy of low- Dal Palù, et al. Calcium antagonist lacidipine slows down dose diuretic monotherapy. Am J Med 1996;101:535-603.
progression of asyntomatic carotid atherosclerosis. Princi- 184. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, pal results of the European Lacidipine Study on Atheros- Black H, et al. Effect of diuretic-based antihypertensive clerosis (ELSA), a randomized, double-blind, long-term treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hy- 200. The Heart Outcomes Prevention Evaluation Study Investi- pertension in the Elderly Program Cooperative Research gators. Effects of an angiotensin-converting-enzyme inhi- bitor, ramipril, on cardiovascular events in high-risk pa- 185. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, tients. N Engl J Med 2000;342:145-53.
et al, for The Randomized Aldactone Evaluation Study In- 200a. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwa- vestigators. The effect of spironolactone on morbidity and la B, et al. On behalf of the HOPE Investigators. Use of ra- mortality in patients with severe heart failure. N Engl J mipril in preventing stroke: double blind randomized 186. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mo- 201. The EUCLID Study Group. Randomised placebo-controlled hacsi P, et al. Effect of carvedilol on survival in severe chro- trial of lisinopril in normotensive patients with insulin- nic heart failure. N Engl J Med 2001;344:1651-8. dependent diabetes and normoalbuminuria or microalbu- 187. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al, for the U.S. Carvedilol Heart Failure 202. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rach- Study Group. The effect of carvedilol on morbidity and mani R. Use of enalapril to attenuate decline in renal mortality in patients with chronic heart failure. N Engl J function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled 188. Escasany AA, Durán M, Arnau JM, Rodríguez D, Fadini ED, trial. Ann Intern Med 1998;128:982-8.
Casas J, et al. Tratamiento médico de la insuficiencia car- 203. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M.
díaca basado en la evidencia. Rev Esp Cardiol 2001;54: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinu- 189. Bristow MR. β-Adrenergic receptor blockade in chronic ria in normotensive type II diabetic patients. Ann Intern heart failure. Circulation 2001;101:558-69.
189a. Farrell MH, Foody JAM, Krumholz HM. β-Blockers in heart 204. Viberti G, Mogensen CE, Groop LC, Pauls JF, for the Euro- pean Microalbuminuria Captopril Study Group. Effect of 190. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Anti- captopril on progression to clinical proteinuria in patients kainen R, Bulpitt CJ, et al, for the Systolic Hypertension in with insulin-dependent diabetes mellitus and microalbu- Europe Trial Investigators. Effect of calcium-channel blo- kade in older patients with diabetes and systolic hyperten- 205. Gæde P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes 191. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Rag- mellitus and microalbuminuria: the Steno type 2 rando- hunathan TE, Weiss NS, et al. The risk of myocardial in- mised study. Lancet 1999;353:617-22.
farction associated with antihypertensive drug therapies.
206. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus 192. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, and microalbuminuria receive angiotensin-converting Schrier RW. The effect of nisoldipine as compared with enzyme inhibitors. A meta-analysis of individual patient enalapril on cardiovascular outcomes in patients with data. Ann Intern Med 2001;134:370-9.
non-insulin-dependent diabetes and hypertension. N Engl 207. Parving HH, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: diabetic nephropathy. Curr 193. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Opin Nephrol Hypertens 2001;10:515-22.
Strollo G, et al. Outcome results of the Fosinopril Versus 208. Heart Outcomes Prevention Evaluation (HOPE) Study In- Amlodipine Cardiovascular Events Randomized Trial (FA- vestigators. Effects of ramipril on cardiovascular and mi- CET) in patients with hypertension and NIDDM. Diabetes crovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
194. Pahor M, Psaty BM, Alderman MH, Applegate WB, Wi- lliamson JD, Cavazzini C, et al. Health outcomes associa- 209. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, ted with calcium antagonists compared with other first-line Montolese M, et al. and the Angiotensin-converting-enzy- Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 me Inhibition in Progressive Renal Insufficiency study sion really resistant? Am J Hypertens 2001;14:1263-9.
group. Effect of the angiotensin-converting-enzyme inhi- 226. Meade TW, Brennan PJ. Determination of who may deri- bitor benazepril on the progression of renal insufficiency.
ve most benefit from aspirin in primary prevention: sub- group results from a randomised controlled trial. BMJ 2000; 210. The GISEN Group (Gruppo Italiano di Studi Epidemiologi- ci in Nefrologia). Randomized placebo controlled trial of 227. Collaborative Group of the Primary Prevention Project effect of ramipril on decline in glomerular filtration rate (PPP). Low-dose aspirin and vitamin E in people at car- and risk of terminal renal failure in proteinuric, non-dia- diovascular risk: a randomised trial in general practice.
betic nephropathy. Lancet 1997;349:1857-63.
211. Segura J, Campo C, Rodicio JL, Ruilope LM. ACE inhibi- 228. Hebert PR, Hennekens CH. An overview of the 4 rando- tors and appearance of renal events in hypertensive nephros- mized trials of aspirin therapy in the primary prevention clerosis. Hypertension 2001;38:645-9.
of vascular disease. Arch Intern Med 2000;160:3123-7.
212. Jaffar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuz- 229. Lip GYH, Edmunds E, Beevers DG. Should patients with zi G, et al, for the ACE Inhibition in Progressive Renal Di- hypertension receive antithrombotic therapy. J Intern Med sease Study Group. Angiotensin-converting enzyme inhi- bitors and progression of nondiabetic renal disease. Ann 230. U.S. Preventive Services Task Force. Aspirin for the pri- mary prevention of cardiovascular events: recommenda- 213. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, tion and rationale. Ann Intern Med 2002;136:157-60.
Cuddy TE, et al, on behalf of the SAVE investigators. Effect 231. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for of captopril on mortality and morbidity in patients with the primary prevention of cardiovascular events: a sum- left ventricular dysfunction after myocardial infarction.
mary of the evidence for the U.S. Preventive Services Task Results of the Survival and Ventricular Enlargement Trial.
Force. Ann Intern Med 2002;136:161-71.
231a. Antithrombotic Trialists’ Collaboration. Collaborative 214. The Acute Infarction Ramipril Efficacy (AIRE) Study Inves- meta-analysis of randomised trials of antiplatelet therapy tigators. Effect of ramipril on mortalilty and morbidity of for prevention of death, myocardial infarction, and stroke survivors of acute myocardial infarction with clinical evi- in high risk patients. BMJ 2002;324:71-86.
dence of heart failure. Lancet 1993;342:821-8.
231b. Lauer MS. Aspirin for primary prevention of coronary 215. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, events. N Engl J Med 2002;346:1468-74.
Lyngborg K, et al, for the Trandolapril Cardiac Evaluation 232. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer R, Mac- (TRACE) Study Group. A clinical trial of the angiotensin- Farlane PW, et al. Prevention of coronary heart disease converting-enzyme inhibitor trandolapril in patients with with pravastatin in men with hypercholesterolemia. N left ventricular dysfunction after myocardial infarction. N 233. Downs J, Clearfield M, Wers S, Whitney E, Shapiro DR, 216. GISSI-3: effects of lisinopril and transdermal glyceryl trini- Beere PA, et al, for the AFCAPS/TexCAPS Research Group.
trate singly and together on 6-week mortality and ventri- Primary prevention of acute coronary events with lovasta- cular function after acute myocardial infarction. Gruppo tin in men and women with average cholesterol levels.
Italiano per lo Studio della Sopravvivenza nell´infarto Mio- Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
234. Scandinavian Simvastatin Survival Study Group. Rando- 217. Burnier M, Brunner HR. Angiotensin II receptor antago- mised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Sur- 218. Tamargo J. Antagonistas de los receptores de la angioten- vival Study (4S). Lancet 1994;344:1383-9.
sina II. Med Clin (Barcelona) 2000;114 (Suppl 1):S6-S13.
235. Sacks FM, Pfeffer M, Moye LA, Rouleau JL, Rutherford JP, 219. American Diabetes Association. Diabetic nephropathy.
Cole TG, et al. The effect of pravastatin on coronary Diabetes Care 2002;25 (suppl 1):S85-S89.
events after myocardial infarction in patients with average 219a. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, cholesterol levels. N Engl J Med 1996;335:1001-9.
de Faire U, et al, for the LIFE study group. Cardiovascular 236. Fox R. American Heart Association 2001 scientific ses- morbidity and mortality in patients with diabetes in the sions: late-breaking science-statins: the new aspirin? Circu- Losartan Intervention For Endpoint reduction in hyperten- sion study (LIFE): a randomised trial against atenolol. Lan-cet 2002;359:1004-10.
237. Ministerio de Sanidad y Consumo. Control de la coleste- 219b. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, rolemia en España, 2000. Un instrumento para la preven- Olofsson B et al for the SCOPE Study Group. The study on ción cardiovascular. Secretaría General Técnica, Ministe- cognition and prognosis in the elderly (SCOPE). Principal rio de Sanidad y Consumo, ed. Madrid; 2000.
results of a randomised double-blind intervention trial. J 238. Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Executive summary of the 220. Lepor H, Kaplan SA, Klimberg I, Mogley D. Doxazosin for third report of the National Cholesterol Education Pro- benign prostatic hyperplasia. Long-term efficacy and sa- gram (NCEP) Expert Panel on Detection, Evaluation, and fety in hypertensive and normotensive patients. J Urol Treatment of High Blood Cholesterol in Adults (Adult Treat- ment Panel III). JAMA 2001;285:2486-97.
221. The ALLHAT Officers and Coordinators for the ALLHAT 238a. Third report of the National Cholesterol Education Pro- Collaborative Research Group. Major cardiovascular gram (NCEP) Expert Panel on Detection, Evaluation, and events in hypertensive patients randomized to doxazosin Treatment of High Blood Cholesterol in Adults (Adult vs chlorthalidone. The Antihypertensive and Lipid-Lowe- Treatment Panel III): Final Report. US Department of Health ring Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA and Human Services; Public Health Service; National Insti- tutes of Health; National Heart, Lung, and Blood Institute.
222. Ruilope L M, Suárez C. Las asociaciones de fármacos: al- ternativa en el tratamiento de la hipertensión arterial.
238b. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with sim- 223. Materson B, Reda D, Preston R, Cushman W, Massie BM, vastatin in 20,536 high-risk individuals: a randomized Freis ED, et al. Response to a second single antihipertensive placebo-controlled trial. Lancet 2002;360:7-22.
agents use as monotherapy for a hypertensión after 238c. Shepherd J, Blauw GL, Murphy MB, Bollen ELEM, Buc- failure of the initial drug. Arch Intern Med 1995;155:1757-62.
kley BM, Cobbe SM, et al, on behalf of the PROSPER 224. Graves JW. Management of difficult-to-control hyperten- study group. Pravastatin in elderly individuals at risk of sion. Mayo Clin Proc 2000;75:278-84.
vascular disease (PROSPER): a randomized controlled 225. Brown MA, Buddle ML, Martin A. Is resistant hyperten- Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 239. Smith SC, Blair N, Criqui MH, for the Secondary Preven- comparison of fosinopril and nifedipine GITS in patients with tion Panel. Preventing heart attack and death in patients primary renal disease. J Hypertension 2001; 19:1871-6.
with coronary disease. J Am Coll Cardiol 1995;26:292-4.
257. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto 240. Fernández C, Bardaji JL, Concha M, Cordo JC, Cosín J, R, et al for the National Kidney Foundation Hypertension and Magrina J, et al. Guías de práctica clínica de la Sociedad Diabetes Executive Committees Working Group. Preserving Española de Cardiología en la angina estable. Rev Esp renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646-61.
241. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β 257a. Wright JT, Bakris G, Greene T, Agodoa L, Appel LJ, Char- Blockade after myocardial infarction: systematic review leston J, et al, for the African American Study of Kidney and meta regression analysis. BMJ 1999;318:1730-7.
Disease and Hypertension Study Group. Effect of blood 242. The CAPRICORN Investigators. Effect of carvedilol on pressure lowering and antihypertensive drug class on pro- outcome after myocardial infarction in patients with left- gression of hypertensive kidney disease. Results from the ventricular dysfunction: the CAPRICORN randomised 257b. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, 242a. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Ideura T. Combination treatment of angiotensin-II receptor Committee, for the OPTIMAAL Study Group. Effects of lo- blocker and angiotensin-converting-enzyme inhibitor in sartan and captopril on mortality and morbidity in high-risk non-diabetic renal disease (COOPERATIVE): a randomi- patients after acute myocardial infarction: the OPTIMAAL zed controlled trial. Lancet 2003;361:117-24.
randomised trial. Lancet 2002;360:752-60.
258. Jacobson H. Ischemic renal disease. Kidney Int 1988; 243. Davis RC, Hobbs FD, Lip GYH. ABC of heart failure: his- tory and epidemiology. BMJ 2000;320:39-42.
259. Alcázar JM, Rodicio JL. Ischemic nephropathy: clinical 244. Moser M, Herbert PR. Prevention of disease progression, characteristics and treatment. Am J Kidney Dis 2000;36: left ventricular hypertrophy, and congestive heart failure in hypertension treatment trial. J Am Coll Cardiol 1996; 260. McLaughlin K, Jardine AG, Moss JG. Renal artery stenosis.
245. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricu- 261. Mann SJ, Pickering TG. Detection of renovascular hyperten- lar hypertrophy in hypertensive patients. A metaanalysis sion. State of art: 1992. Ann Intern Med 1992;117:845-53.
of 109 treatment studies. Am J Hypertens 1992;5:95-110.
262. Marín R, Fernández-Vega F, Escalada P, Estevan JM, Barreiro 246. Schmieder R, Martus P, Klingbell A. Reversal of left ventri- A, Álvarez J. Factores de riesgo cardiovascular en la enfer- cular hypertrophy in essential hypertension. A meta- medad arterial periférica. Rev Clin Esp 1993;193: 357-62.
analysis of randomized double-blind studies. JAMA 263. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
247. Dahlöf B. Left ventricular hypertrophy and angiotensin II 264. Makin A, Lip GYH, Silverman S, Beevers DG. Peripheral receptor antagonists. Am J Hypertens 2001;14:174-82.
vascular disease and hypertension: a forgotten associa- 248. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, tion? J Hum Hypertens 2001;15:447-54.
de Faire U, et al. Characteristics of 9194 patients with left 265. Black HR. The paradigm has shifted to systolic blood ventricular hypertrophy: the LIFE study. Losartan Interven- pressure. Hypertension 1999;34:386-7.
tion For Endpoint reduction in hypertension. Hyperten- 266. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and ge- 249. Benjamin EJ, Levy D, Varizi SM. Independent risk factors neralizability of randomized trials. JAMA 1994;272: 1932-8.
for atrial fibrillation in a population-based cohort: the Fra- 267. Black HR, Elliott WJ, Weber MA, Frishman WH, Strom JA, mingham Heart Study. JAMA 1994;271:840-4.
Liebson PR, et al, for the Stage 1 Systolic Hypertension 250. Copland M, Walker ID, Tait RC. Oral anticoagulation and (SISH) Study Group. One-year study of felodipine or pla- hemorrhagic complications in an elderly population with cebo for stage 1 isolated systolic hypertension. Hyperten- atrial fibrillation. Arch Intern Med 2001;161:2125-8.
250 a. Peters NS, Schilling RJ, Kanagaratnam P, Markides V.
268. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fa- Atrial fibrillation: strategies to control, combat, and cure.
gard R, et al, for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of 251. The INDANA Project Collaborators. Effect of antihyper- randomised controlled trials. Lancet 1999;353:793-6.
tensive treatment in patients having already suffered from 269. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, stroke: gathering the evidence. Stroke 1997;28:2557-62.
Forette F, et al. Hypertension in the Very Elderly Trial (HYVET): 251a. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, protocol for the main trial. Drugs Aging 2001;18:151-64.
Babeanu S, et al, for the Syst-Investigators. The prevention 270. Beevers DG, Lip GYP. The protective effect of blocking of dementia with antihypertensive treatment. Arch Intern angiotensin in both type I and type II diabetics with nephro- pathy. J Hum Hypertens 2001;15:837-9.
252. Marín R, Gorostidi M. Nefroesclerosis. En: Hernando L, 271. Laakso M. Benefits of strict glucose and blood pressure Aljama P, Arias M, Caramelo C, Egido J, Lamas S, edito- control in type 2 diabetes: lessons from the UK Prospecti- res. Nefrología clínica. Madrid: Editorial Médica Paname- ve Diabetes Study. Circulation 1999;99:461-2.
272. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ, and the 253. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Collaborative Study Group. Effect of intensive blood pres- Wedel H, et al. Renal function and intensive lowering of sure control on the course of type 1 diabetic nephropathy.
blood pressure in hypertensive participants of the Hyper- tension Optimal Treatment (HOT) study. J Am Soc Nephrol 273. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular compli- 254. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the cations in patients with hypertension and type 2 diabetes.
HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the 274. Sociedades Españolas de Diabetes, Endocrinología, Medi- HOPE randomized trial. Ann Intern Med 2001;134:629-36.
cina Familiar y Comunitaria y Nefrología. Documento de 255. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, consenso sobre pautas de detección y tratamiento de la ne- Hunsicker LG, et al for the Modification of Diet in Renal fropatía diabética en España. Nefrología 1997;17:467-74.
Disease (MDRD) Study Group. Blood pressure control, 274a. Viberti G, Wheeldon NM, for the MicroAlbuminuria Re- proteinuria, and the progression of renal disease. Ann In- duction with VALsartan (MARVAL) Study Investigators. Mi- croalbuminuria reduction with valsartan in patients with ty- 256. Marín R, Ruilope LM, Aljama P, Aranda P, Segura J, Díez J, pe 2 diabetes mellitus. A blood pressure-independent on behalf of the investigators of the ESPIRAL study. A random Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 274b. Asociación Española de Nefrología Pediátrica (AEN-PED), 291a. Rosenthal T, Oparil S. The effect of antihypertensive drug Sociedades Españolas de Diabetes (SEDIAB), Endocrinolo- on the fetus. J Hum Hypertens 2002;16:293-8.
gía y Nutrición (SEEN), Hipertensión-Liga Española para la 292. Kaplan NM. Hypertension with pregnancy and the pill.
Lucha contra la Hipertensión Arterial (SEHLELHA), Medici- En: Kaplan NM, editor. Clinical hypertension. Baltimore: na Familiar y Comunitaria (SEMFYC), Medicina Rural y Ge- Williams & Wilkins; 1998. p. 323-44.
neralista (SEMERGEN) y Nefrología (SEN). Pautas de detec- 293. Aranda P, Aranda FJ, Aranda PJ. Hipertensión arterial y ción, prevención y tratamiento de la nefropatía diabética menopausia. En: Aranda P, ed. Hipertensiones secunda- en España. Hipertensión 2002;19:412-20.
rias en poblaciones especiales (menopausia, embarazo, 274c. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pe- obesidad y diabetes). Biblioteca Básica SEHLELHA. Ma- dersen O. Multifactorial intervention and cardiovascular di- sease in patients with type 2 diabetes. N Engl J Med 2003; 294. Skegg DCG. Hormone therapy and heart disease after the 275. Aranda P, Aranda FJ, Aranda PJ. Hipertensión arterial e hi- 295. Lieberman E. Hypertension in childhood and adolescen- perlipemia. En: Aranda P, Coca A, Palma JL, editores. ce. En: Kaplan NM, editor. Clinical Hypertension 7th Ed.
Cuadernos Latinoamericanos de Hipertensión. Volumen II.
Baltimore: Williams & Wilkins; 1998. p. 407-20.
296. Erstad BL, Barletta JF. Treatment of hypertension in the pe- 276. Aranda P, Rodicio JL, Luque M, Banegas JR, Barajas R, rioperative patient. Ann Pharmacother 2000;34:66-79.
Aranda FJ, et al. Cholesterol levels in untreated spanish 297. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, hypertensive patients. Blood Pressure 2000;9:1-16.
Kochar MS, et al. Single-drug therapy for hypertension in 277. Grim Jr RH, Flack JM, Grandits GA, Elmer PJ, Neaton JN, men. A comparison of six antihypertensive agents with Cutler JA, et al. Long-term effects on plasma lipids of diet placebo. The Department of Veterans Affairs Cooperative and drugs to treat hypertension. JAMA 1996;275:1549- Study Group on Antihypertensive Agents. N Engl J Med 278. Aranda P, Villar J, en representación del Grupo Colabora- 298. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, tivo Andaluz. Prevalencia de factores de riesgo vascular Briggs JP, et al. Effect of ramipril vs amlodipine on renal en Andalucía. Estudio Al-Andalus 90. Consejería de Sa- outcomes in hypertensive nephrosclerosis: a randomized lud, Servicio Andaluz de Salud, ed. Sevilla: Consejería de controlled trial. JAMA 2001;285:2719-28.
Salud, Servicio Andaluz de Salud; 1993.
299. Tovar JL, Álvarez-Sabín J, Armario P, por el Comité de las 279. Reaven GM, Lithell H, Landsberg L. Hypertension and asso- Sociedades Catalanas de Hipertensión Arterial y de Neu- ciated metabolic abnormalities – the role of insulin resis- rología. Tratamiento del aumento de presión arterial en la tance and the sympathoadrenal system. N Engl J Med fase aguda del ictus. Recomendaciones de las Sociedades Catalanas de Hipertensión Arterial y de Neurología. Rev 280. Jones DW. Body weight and blood pressure. Effects of weight reduction on hypertension. Am J Hypertens 1996; 300. Kitiyakara C, Guzman NJ. Malignant hypertension and hy- pertensive emergencies. J Am Soc Nephrol 1998;9:133-42.
281. Després J-P. Drug treatment for obesity. BMJ 2001; 301. Alcázar JM. Uso y abuso del nifedipino sublingual. Hiper- 282. Arterburn D, Noël PH. Obesity. BMJ 2001;322:1406-9.
302. Gorostidi M, Baeza A, Jáuregui A, Marín R. Urgencias en 282a. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; hipertensión arterial. Hipertensión 1999;16:90-9.
303. Vaughan CJ, Delanty N. Hypertensive emergencies. Lan- 283. Beevers DG, Lip GYH. Is uric acid really an independent cardiovascular risk factor? Lancet 1998;352:1556.
304. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, 284. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric Kannel WB, Levy D. Impact of high-normal blood pressu- acid and risk for cardiovascular disease and death: the re on the risk of cardiovascular disease. N Engl J Med Framingham Heart Study. Ann Intern Med 1999;131:7-13.
285. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab- 305. Vasan RS, Larson MG, Leip EP, Kannel W, Levy D. Assess- Stubi CL, Brunner HR, et al. Comparative effects of losar- ment of frequency of progression to hypertension in non- tan and irbesartan on serum uric acid in hypertensive pa- hypertensive participants in the Framingham Heart Study: tients with hyperuricemia and gout. J Hypertens 2001; a cohort Study. Lancet 2001;358:1682-6.
286. Lunde H, Hedner T, Samuelsson O, Lotvall J, Andren L, 306. Cohn JN. Arterial compliance to stratify cardiovascular Lindholm L, et al. Dyspnoea, asthma, and bronchospasm risk: more precision in therapeutic decision making. Am J in relation to treatment with angiotensin converting enzy- 307. Fagard RH, Staessen J, Thijs L. Prediction of cardiac struc- 287. Mayer J, Becker H, Brandenburg U, Penzel T, Peter JH, ture and function by repeated clinic and ambulatory pres- von Wichert P. Blood pressure and sleep apnea: results of long-term nasal continuous positive airway pressure the- 308. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari, et al. Ambulatory blood pressure is su- 288. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, perior to clinic blood pressure in predicting treatment-in- Niroumand M, et al. High prevalence of unrecognized duced regression of left ventricular hypertrophy. Circula- sleep apnoea in drug-resistant hypertension. J Hypertens 309. Pascual JM, Baldó E, Bertolin V, Rovira E, Gonzalvo F, 289. Marín R, Portal CG, Gorostidi M, Sánchez M, Sánchez E, Fer- González C, et al. Presión arterial ambulatoria e hipertro- nández-Vega F, Álvarez-Grande J. Hipertensión arterial en el fia ventricular izquierda en hipertensos no tratados. Med embarazo: estudio de 864 casos consecutivos observados durante un período de 24 años. Nefrología 1999;19:308-17.
310. Redon J, Miralles A, Liao Y, Lozano JV, Pascual JM, Coo- 290. Barth W. Low-dose aspirin for preeclampsia – the unresol- per RS. Circadian variability and microalbuminuria in es- ved question. N Engl J Med 1998;338:756-7.
sential hypertension. J Hypertens 1994;12:947-54.
290a. The Magpie Trial Collaborative Group. Do women with 311. Verdecchia P. Prognostic value of ambulatory blood pres- pre-eclampsia, and their babies, benefit from magnesium sure: current evidence and clinical implications. Hyper- suphate? The Magpie Trial: randomized placebo-con- trolled trial. Lancet 2002;359:1877-90.
312. Ruilope LM, Schiffrin EL. Blood pressure control and be- 291. Marín R, Gorostidi M, Portal CG, Sánchez M, Sánchez E, nefits of antihypertensive therapy: does it make a differen- Álvarez J. Long- term prognosis of hypertension in preg- ce which agents we use? Hypertension. 2001;38:537-42.
nancy. Hypertens Pregnancy 2000;19:199-209.
313. Lifton RP. Genetic determinants of human hypertension.
Hipertensión 2002;19 Suppl 3:60-9 GUÍA SOBRE EL DIAGNÓSTICO Y EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL EN ESPAÑA 2002 adjunct for global risk assessment in the primary prevention 314. Ward R. Familial aggregation and genetic epidemiology of cardiovascular disease. Circulation 2001;103: 1813-8.
of blood pressure. En: Laragh JH, Brenner BM, editores.
321. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. In- Hypertension: Pathophysiology, Diagnosis and Manage- tima-media thickness: a new tool for diagnosis and treat- ment. Nueva York: Raven Press Ltd; 1995. p. 67-88.
ment of cardiovascular risk. J Hyp∫2;20:159-69.
315. Lander ES, Schork NJ. Genetic dissection of complex 322. Padwal R, Straus SE, McAlister FA. Evidence based mana- gement of hypertension. Cardiovascular risk factors and 316. Lurbe E, Redon J, Álvarez V, Durazo R, Gómez A, Tacons J, their effects on the decision to treat hypertension: eviden- et al. Relationship between birth weight and awake ce based review. BMJ. 2001;322:977-80.
blood pressure in children and adolescents in absence of 323. Nichols-English G, Poirier S. Optimizing adherence to intrauterine growth retardation. Am J Hypertens 1996;9: pharmaceutical care plans. J Am Pharm Assoc. 2000;40: 317. Kroke A, Bergmann M, Klipstein-Grobusch K, Boeing H.
324. Clozel M. Endothelin receptor antagonists: current status and Obesity, body fat distribution and body build: their rela perspectives. J Cardiovasc Pharmacol. 2000;35(Suppl 2): tion to blood pressure and prevalence of hypertension. Int J Obes Relat Metb Disord 1998;22:1062-70.
325. Asher JR, Naftilan AJ. Vasopeptidase inhibition: a new di- 318. Kolanowski J. Obesity and hypertension: from pathophy- rection in cardiovascular treatment. Curr Hypertens Rep.
siology to treatment. Int J Obes Relat Metab Disord 1999; 325a. Cotas AJS. Omapatrilat. The story of overture and octave.
319. Smith SC Jr, Greenland P, Grundy SM. Prevention Confe- rence V. Beyond Secondary Prevention: Identifying the 325b. Tojo A, Fujita T, Wilcox CS. Omapatrilat: still a promise High-Risk Patient for Primary Prevention: Executive Sum- in salt-sensitive hypertension? J Hypertens 2003; 21:31-2.
325c. Boehm M, Nabel EG. Angiotensin-converting enzyme 2.
320. Ridker PM. High-sensitivity C-reactive protein: potential A new cardiac regulation. N Engl J Med 2002; 347:1795-7.
Hipertensión 2002;19 Suppl 3:60-9

Source: http://www.seh-lelha.org/pdf/guiaBibliografia.pdf